High conversion rates to Parkinson's, dementia with Lewy bodies, or multiple system atroph ...

Multiple system atrophy (MSA) is an adult-onset, rapidly progressive neurodegenerative disorder characterised by the aggregation of α-synuclein in oligodendroglial cytoplasmatic inclusions.1 ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program - - Positive feedback supports readiness for Phase 3 initiation with manufacturing ...

ABLi Therapeutics (“ABLi”), a biotechnology company developing therapeutics to address diseases that arise from activation of Abelson Tyrosine Kinases (c-Abl kinases), announces the appointment of ...

Brent crude briefly dumped below US$100 a barrel, while gold and silver surged as bond yields slid lower. Back on the ASX, ...

News and commentary from the world of neurology and neuroscience ...

Ametefgene parvec (AB-1005) manufactured at Viralgen commercial manufacturing facility with next-generation process to deliver high-purity product with greater efficiency   AskBio Inc. (AskBio), a ...

Alignment reached on chemistry, manufacturing, and control (CMC) elements of ATH434 Phase 3 development program – – Positive feedback supports readiness for Phase 3 initiation with manufacturing scale ...

As of Tuesday, April 21, Alterity Therapeutics Limited’s ATHE share price has dipped by 8.54%, which has investors questioning if this is right time to buy.

Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.